CAMBRIDGE, ONTARIO (October 2, 2015) – Virbac Canada Inc. today announced the launch of Pronefra™ Palatable Oral Suspension, a new Virbac product that supports the normal function and health of kidneys in cats and dogs.

Pronefra™ Palatable Oral Suspension is a unique 4-in-1 suspension with a combination of two intestinal phosphate binders (IPB): calcium carbonate and magnesium carbonate. This new product is designed with enhanced palatability, can be administered directly in the mouth and is supported by a published palatability study with a result of “95% willingly accepted by cats”. Additionally, Pronefra™ Palatable Oral Suspension provides two more benefits: contributes to the maintenance of normal kidney architecture and helps support normal blood pressure.

"Pronefra™ Palatable Oral Suspension provides an option to better equip our Canadian customers in the support of renal health,” stated Fiona J. McLellan, Virbac Canada general manager. “We understand that patient inappetence is a major barrier to successful treatment, especially in cats. Development focused on solving this problem, simplifying the pet owners’ effort while increasing adherence. Our goal is to provide products that will help strengthen the bond between pet owner, pet and veterinary clinic, while improving the quality of the life for the patient. Pronefra™ Palatable Oral Suspension will help do that.”

Recently notified as a Low-Risk Veterinary Health Product (LRVHP), it is currently available from the Veterinary Purchasing Groups.